Paris, 29 July 2013

Novel molecules to target the cytoskeleton

The dysfunction of the cytoskeleton, a constituent element of the cell, is often associated with pathologies such as the onset of metastases. For this reason, it is a target of interest in numerous therapies. Teams from CNRS, the Université de Strasbourg and Inserm, led by Daniel Riveline1, Jean-Marie Lehn2 and Marie-France Carlier3, have synthesized molecules capable of causing rapid growth of actin networks, one of the components of the cytoskeleton. This is a breakthrough because, until now, only molecules that stabilize or destroy the cytoskeleton of actin have been available. These compounds with novel properties, whose action has been elucidated both in vitro and in vivo, provide a new tool in pharmacology. This work was published in the journal Nature Communications on 29 July 2013.

To download the press release : cytosquelette


1Institut de Science et d'Ingénierie Supramoléculaires (CNRS/Université de Strasbourg) and Institut de Génétique et de Biologie Moléculaire et Cellulaire (CNRS/Université de Strasbourg/Inserm).
2Institut de Science et d'Ingénierie Supramoléculaires (CNRS/Université de Strasbourg).
3Laboratoire d'Enzymologie et Biochimie Structurales of CNRS.


Synthetic polyamines promote rapid lamellipodial growth by regulating actin dynamics.
Iliana Nedeva, Girish Koripelly, David Caballero, Lionel Chièze, Bérangère Guichard, Benoît Romain, Erwan Pencreach, Jean-Marie Lehn, Marie-France Carlier, Daniel Riveline.
Nature communications, 29 July 2013. DOI: 10.1038/ncomms3165


Researcher l Daniel Riveline l T +33 3 68 85 51 64 l
CNRS press officer l Priscilla Dacher l T +33 1 44 96 46 06 / 51 51 l


Latest press releases

All disciplines

Back to homepageContactcredits